A Phase 1 Study to Evaluate the Safety, Tolerability, PK/PD of SRSD107 in Healthy Participants

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 23, 2024

Primary Completion Date

December 9, 2024

Study Completion Date

April 30, 2025

Conditions

Thrombosis

Interventions

DRUG

SRSD107

SRSD107 is a synthetic, chemically modified double-stranded, small interfering ribonucleic acid (siRNA).

DRUG

Placebo

Sodium chloride

Trial Locations (1)

Linear Clinical Research, Perth

All Listed Sponsors

lead

Sirius Therapeutics Co., Ltd.

INDUSTRY

NCT06116617 - A Phase 1 Study to Evaluate the Safety, Tolerability, PK/PD of SRSD107 in Healthy Participants | Biotech Hunter | Biotech Hunter